Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04205500
Active, not recruiting Not applicable

Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis

NCT04205500 · tracked via the Priya Life Science Sweden tracker
Sponsor
Uppsala University
Phase
Not applicable
Started
2017-09-01
Last updated
2026-08-28

Condition(s) studied

Juvenile Idiopathic Arthritis

Investigational drug(s) / intervention(s)

Specific carbohydrate diet

Specific carbohydrate diet: Specific carbohydrate diet (see arm description)

Study summary

The aim of this study is to explore if an already established diet with anti-inflammatory effect in paediatric inflammatory bowel disease would have an anti-inflammatory effect in children with JIA. The diet is called specific carbohydrate diet.

Eligibility

Sex
ALL
Min age
—
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Participants should fulfill criteria for JIA according to the ILAR criteria * Participants should not be older than 16 years at onset of disease * Participants should have a low-medium disease activity with an E-SR of 30 at the most and/or no more than two active joints at inclusion. * DMARD and bDMARD should not have been changed within the last 12 weeks before inclusion. * Any gastro- intestinal complaints should be investigated before inclusion. * Fecal calprotectin should be normal. * The child as well as the parents need to be motivated for the child to try a dietary intervention for at least four weeks, preferably longer. Exclusion criteria: * Children with the systemic category of JIA. * Children with an unstable inflammatory situation with \> 2 inflamed joints and/or an E-SR of more than 30.

Primary outcome measure(s)

  • Change in number of inflamed joints — At baseline compared to four weeks of intervention
    Physical examination
  • Change in CHAQ, child health assessment questionnaire — At baseline compared to four weeks of intervention
    A questionnaire for assessment of physical function, min-max, 0-3. A higher score means worse physical function
  • Change in overall well-being — At baseline compared to four weeks of intervention
    Global assessment visual analogue scale (VAS), for the patient min-max, 0-10 cm. A higher score means worse overall well-being
  • Change in assessment of pain: visual analogue scale — At baseline compared to four weeks of intervention
    Global assessment visual analogue scale (VAS) for Pain, min-max, 0-10 cm. A higher score means more pain
  • Change in assessment of morning stiffness — At baseline compared to four weeks of intervention
    Number of minutes

Trial sites (1)

FacilityCityRegionStatus
Uppsala university Uppsala Uppsala County

More Uppsala University trials in Sweden

Efficacy of Hyperthermic Intraperitoneal Chemotherapy Recruiting
Robotic-Assisted Pedicle Screw Placement in Spine Surgery Recruiting
The Scandinavian Displaced Lateral Clavicle Trial Recruiting
Fusion or Not - a Study on Low Back Pain Recruiting
Nutrition and Inflammation in Patients With Head and Neck Cancer Active, not recruiting

Other trials for the same condition

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04205500 on ClinicalTrials.gov ↗ ← All trials in Sweden